Tuesday, 22 September 2020

18:00 CEST / 12:00 EDT / 09:00 PDT*

*make sure that your time zone
fits the time of the livestream.

  • Twitter
  • Facebook
  • LinkedIn
  • YouTube
#RTsymposium2020

Inhibition of the reverse transcriptase enzyme has played a critical role in the treatment and prevention of HIV from the earliest days of the epidemic through to the present.

Although current antiretroviral (ARV) therapies effectively control HIV in the majority of patients, unmet needs remain, including reduced toxicity, improved dosing, more convenient delivery, and long-term prevention of resistance.  In the absence of an effective HIV vaccine and/or a cure regimen, it is imperative that ARV drug pipelines continue to pursue new and improved options.

Important new data on next generation reverse transcriptase inhibitors (RTIs) is being presented and published at an increasingly rapid rate.  This 3-hour virtual program offers an educational opportunity for healthcare practitioners to both revisit the history of RTIs and become informed of recent developments in the field.  In particular, this program will present and discuss preclinical and clinical information regarding 3 classes of RTIs:  NRTIs, NNRTIs, and NRTTIs.

Program Director

Jonathan Schapiro MD

Sheba Medical Centre

Tel Aviv, Israel

PROGRAM

18:00

CEST

Welcome
Opening of Virtual Symposium

Jonathan Schapiro MD
Scheba Medical Centre
Tel Aviv Israel
18:10

CEST

Historical perspective:
Inhibiting the RT enzyme and curtailing the AIDS pandemic

To be confirmed
18:25

CEST

Mechanisms of action: NNRTI

Daniel Kuritzkes MD
Brigham and Women's Hospital/ Harvard Medical School
New York City, United states
18:40

CEST

Mechanisms of action: NRTI and NRTTI
To be confirmed
19:00

CEST

Q & A of Question submitted online by viewers
19:20

CEST

Short Break
19:30

CEST

Clinical Review: New RT inhibitors – Doravirine
Chloe Orkin MBChB, FRCP, MD
Barts Health NHS Trust
London, United Kingdom
19:50

CEST

Clinical Review: New RT inhibitors –  Islatravir
Jean-Michel Molina MD
Hôpital Saint Louis
Paris, France
20:10

CEST

Toxicity of different drugs classes and their clinical implication
To be Confirmed
20:25

CEST

Optimal use of NRTTI + NNRTI regimens in routine clinic practice
Anton Pozniak MD, FRCP
Chelsea and Westminster Hospital
London, United Kingdom
20:45

CEST

Q & A of Question submitted online by viewers
21:10

CEST

Conclusions
Closure of Virtual Symposium

Jonathan Schapiro MD
Scheba Medical Centre
Tel Aviv Israel
If you have any questions please contact Patrick Conings at patrick@vironet.com
REGISTRATION FEES

 

In order to access this webinar, you must register online. Registration to the Leveraging Reverse Transcriptase in HIV:  Past, Present and Future 2020 is free of charge for all healthcare practitioners*. A registration fee applies to other individuals.


*Healthcare practitioners are defined as professionals that provide a type of health care service to patients living with HIV. Please, contact the Conference Secretariat for more information at patrick@vironet.com if you are not sure.

CORPORATE SUPPORT

Biltstraat 106

3572 BJ, Utrecht, the Netherlands

info@virology-education.com

  • White Twitter Icon
  • White LinkedIn Icon
  • White Facebook Icon

Tel: +31 (0)30 230 7140

© 2020 by Virology Education